Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : YAP–TEAD
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : National Center for Advancing Translational Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the collaboration, NCATS will gain access to proprietary novel proteolysis-targeting degraders of TEAD, including YAP–TEAD, from Beactica to evaluate their efficacy in disease-relevant preclinical models for treatment of cancer.
Brand Name : YAP–TEAD
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 26, 2023
Lead Product(s) : YAP–TEAD
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : National Center for Advancing Translational Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : BEA-17
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Oscotec
Deal Size : $178.0 million
Deal Type : Termination
Beactica Therapeutics and Oscotec Mutually Agree to Conclude Oncology Collaboration
Details : Under the agreement, Beactica Therapeutics will retain full exclusive global rights for further development and commercialization of the LSD1 programme, including BEA-17, a first-in-class small molecule targeted degrader of the epigenetic enzyme LSD1 and...
Brand Name : BEA-17
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 04, 2023
Lead Product(s) : BEA-17
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Oscotec
Deal Size : $178.0 million
Deal Type : Termination
Lead Product(s) : BEA-17
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BEA-17 is a first-in-class small molecule targeted degrader (non-PROTAC) of the epigenetic enzyme LSD1 and its co-factor CoREST. The compound has shown promising preclinical in vivo potentiation of immune-modulating treatments in several cancer forms.
Brand Name : BEA-17
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 01, 2023
Lead Product(s) : BEA-17
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : Dong-A ST Co., Ltd.
Deal Size : Undisclosed
Deal Type : Termination
Dong-A ST and Beactica Therapeutics Mutually Agree to Conclude Oncology Collaboration
Details : As part of the termination, both Dong-A ST and Beactica Therapeutics will gain exclusive global rights for further development and commercialization for different compounds series developed during the collaboration.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 06, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : Dong-A ST Co., Ltd.
Deal Size : Undisclosed
Deal Type : Termination
Details : Under the terms of the agreement, Oscotec is entitled to gain exclusive global rights for further development and commercialization of Beactica's programme.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 02, 2021
LOOKING FOR A SUPPLIER?